Format

Send to

Choose Destination
J BUON. 2019 Nov-Dec;24(6):2475-2482.

The VEGF gene polymorphism in glioblastoma may be a new prognostic marker of overall survival.

Author information

1
Clinic for Radiotherapy, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia.

Abstract

PURPOSE:

Glioblastoma (GBM) is the most aggressive primary brain tumor. Vascular endothelial growth factor (VEGF) gene polymorphisms and overexpression are involved in high-grade malignant gliomas. The aim of this study was to assess the distribution of +405C>G VEGF gene polymorphism in patients diagnosed by glioblastoma and to test its association with the overall survival (OS).

METHODS:

Patients diagnosed for glioblastoma were randomly selected, and follow-up was conducted for a minimum of 36 months. Tissue paraffin embedded GBM samples were subjected for the VEGF polymorphism detection. The associations of the observed genotypes and clinical data were evaluated.

RESULTS:

The most frequent single nucleotide polymorphism (SNP) variant was G (72.58%). The GG genotype was proved to have statistically significant longer OS and patient status (alive/dead) compared to CC and CG genotypes (p=0.022 and 0.005, respectively).

CONCLUSION:

Our results indicate that +405C>G VEGF gene polymorphism may be used as prognostic genetic marker of OS in GBM patients.

PMID:
31983122
Free full text

Supplemental Content

Full text links

Icon for Zerbinis, Medical Publications
Loading ...
Support Center